Key result
Oral propafenone plasma levels of 0.20 to 0.60 mcg/ml are linked to ~63% effective arrhythmia control.
Why the study?
The relationship between oral propafenone plasma concentrations and its anti-arrhythmic efficacy in outpatients was not well characterized.
Does plasma propafenone concentration correlate with anti-arrhythmic efficacy in outpatients with arrhythmias?
Population
70 outpatients with arrhythmias, mean age 57 +/- 12 years
Comparison
Propafenone plasma concentration levels in relation to anti-arrhythmic efficacy
Design
Observational cohort study
Follow-up
24 +/- 32 months
Authors
Loading...
Therapeutic propafenone monitoring may aid outpatient arrhythmia care; leaves open whether concentration-guided dosing improves outcomes in trials.
Observational (n=70)
Does plasma propafenone concentration correlate with anti-arrhythmic efficacy in outpatients with arrhythmias?
Monitoring propafenone and hydroxypropafenone plasma concentrations is a practical method to assess compliance, identify poor metabolizers, and guide anti-arrhythmic therapy, with optimal efficacy observed between 0.20 and 0.60 micrograms/ml.
Steurer et al. (1991) conducted an observational in Arrhythmias (n=70). Oral propafenone therapy was evaluated on Effective control of arrhythmias. Optimal anti-arrhythmic efficacy of oral propafenone was observed at plasma concentrations between 0.20 and 0.60 micrograms/ml, where 63% of patients were effectively treated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: